Cryptococcus neoformans capsular glucuronoxylomannan induces expression of Fas ligand in macrophages

Journal of Immunology

Volumn 174, Issue 6, 2005, Pages 3461-3468

  Monari, Claudia ^a   Pericolini, Eva ^a   Bistoni, Giovanni ^b   Casadevall, Arturo ^c   Kozel, Thomas R ^d   Vecchiarelli, Anna ^a  

^a UNIVERSITY OF PERUGIA   (Italy)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

^c ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^d UNIVERSITY OF NEVADA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FAS ANTIBODY; FAS LIGAND; GLUCURONOXYLOMANNAN; MANNAN; POLYSACCHARIDE; TOLL LIKE RECEPTOR 4; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CELLS AND CELL COMPONENTS; CRYPTOCOCCUS NEOFORMANS; CYTOTOXICITY; HOMEOSTASIS; HUMAN; HUMAN CELL; IMMUNOPATHOLOGY; IMMUNOREGULATION; LEUKEMIA CELL LINE; MACROPHAGE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; PROTEIN SYNTHESIS; PROTEIN TRANSPORT; T LYMPHOCYTE; UPREGULATION;

EID: 14844340836     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.174.6.3461     Document Type: Article

References (76)

1. Brain, J. D. 1985. Macrophages in the respiratory tract. In Handbook of Physiology: The Respiratory System. A. P. Fishman, A. B. Fisher, and S. R. Geiger, eds. Waverly, Baltimore, p. 457.
2. Lafferty, K. J., S. J. Prowse, C. J. Simeonovic, and H. S. Warren. 1983. Immunobiology of tissue transplantation: a return to the passenger leukocyte concept. Ann. Rev. Immunol. 1:143.
3. Talmage, D. W., G. Dan, J. Radovich, and K. J. Lafferty. 1976. Activation of transplant immunity: effect of donor leukocytes on thyroid allograft rejection. Science 191:385.
4. La Rosa, F. G., and D. W. Talmage. 1983. The failure of a major histocompatibility antigen to stimulate a thyroid allograft reaction after culture in oxygen. J. Exp. Med. 157:898.
5. Lafferty, K. J., A. Bootes, G. Dart, and D. W. Talmage. 1976. Effect of organ culture on the survival of thyroid allografts in mice. Transplantation 22:138.
6. Li, J. H., D. Rosen, D. Ronen, C. K. Behrens, P. H. Krammer, W. R. Clark, and G. Berke. 1998. The regulation of CD95 ligand expression and function in CTL. J. Immunol. 161:3943.
7. Wells, A. D., X. C. Li, Y. Li, M. C. Walsh, X. X. Zheng, Z. Wu, G. Nunez, A. Tang, M. Sayegh, W. W. Hancock, et al. 1999. Requirement for T-cell apoptosis in the induction of peripheral transplantation tolerance. Nat. Med. 5:1303.
8. Cascino, I., G. Fiucci, G. Papoff, and G. Ruberti. 1995. Three functional soluble forms of the human apoptosis-inducing Fas molecule are produced by alternative splicing. J. Immunol. 154:2706.
9. Klas, C., K. M. Debatin, R. R. Jonker, and P. H. Krammer. 1993. Activation interferes with the APO-1 pathway in mature human T cells. Int. Immunol. 5:625.
10. Leithauser, F., J. Dhein, G. Mechtersheimer, K. Koretz, S. Bruderlein, C. Henne, A. Schmidt, K. M. Debatin, P. H. Krammer, and P. Moller. 1993. Constitutive and induced expression of APO-1, a new member of the nerve growth factor/tumor necrosis factor receptor superfamily, in normal and neoplastic cells. Lab. Invest. 69:415.
11. Suda, T., and S. Nagata. 1994. Purification and characterization of the Fas-ligand that induces apoptosis. J. Exp. Med. 179:873.
12. Takahashi, T., M. Tanaka, J. Inazawa, T. Abe, T. Suda, and S. Nagata. 1994. Human Fas ligand: gene structure, chromosomal location and species specificity. Int. Immunol. 6:1567.
13. Suda, T., T. Takahashi, P. Golstein, and S. Nagata. 1993. Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family. Cell 75:1169.
14. Itoh, N., S. Yonehara, A. Ishii, M. Yonehara, S. Mizushima, M. Sameshima, A. Hase, Y. Seto, and S. Nagata. 1991. The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis. Cell 66:233.
15. Miyawaki, T., T. Uehara, R. Nibu, T. Tsuji, A. Yachie, S. Yonehara, and N. Taniguchi. 1992. Differential expression of apoptosis-related Fas antigen on lymphocyte subpopulations in human peripheral blood. J. Immunol 149:3753.
16. Liles, W. C., P. A. Kiener, J. A. Ledbetter, A. Aruffo, and S. J. Klebanoff. 1996. Differential expression of Fas (CD95) and Fas ligand on normal human phagocytes: implications for the regulation of apoptosis in neutrophils. J. Exp. Med. 184:429.
17. Schattner, E., and S. M. Friedman. 1996. Fas expression and apoptosis in human B cells. Immunol. Res. 15:246.
18. Tanaka, M., T. Suda, T. Takahashi, and S. Nagata. 1995. Expression of the functional soluble form of human Fas ligand in activated lymphocytes. EMBO J. 14:1129.
19. Hahne, M., T. Renno, M. Schroeter, M. Irmler, L. French, T. Bornard, H. R. MacDonald, and J. Tschopp. 1996. Activated B cells express functional Fas ligand. Eur. J. Immunol. 26:721.
20. Suda, T., T. Okazaki, Y. Naito, T. Yokota, N. Aral, S. Otaki, K. Nakao, and S. Nagata. 1995. Expression of the Fas ligand in cells of T cell lineage. J. Immunol. 154:3806.
21. Griffith, T. S., T. Brunner, S. M. Fletcher, D. R. Green, and T. A. Ferguson. 1995. Fas ligand-induced apoptosis as a mechanism of immune privilege. Science 270:1189.
22. Tzianabos, A. O. 2000. Polysaccharide immunomodulators as therapeutic agents: structural aspects and biologic function. Clin. Microbiol. Rev. 13:523.
23. Vecchiarelli, A., C. Retini, D. Pietrella, C. Monari, C. Tascini, T. Beccari, and T. R. Kozel. 1995. Down-regulation by cryptococcal polysaccharide of tumor necrosis factor α and interleukin-1 β secretion from human monocytes. Infect. Immun. 63:2919.
24. Retini, C., T. R. Kozel, D. Pietrella, C. Monari, F. Bistoni, and A. Vecchiarelli. 2001. Interdependency of interleukin-10 and interleukin-12 in regulation of T-cell differentiation and effector function of monocytes in response to stimulation with Cryptococcus neoformans. Infect. Immun. 69:6064.
25. Vecchiarelli, A., D. Pietrella, P. Lupo, F. Bistoni, D. C. McFadden, and A. Casadevall. 2003. The polysaccharide capsule of Cryptococcus neoformans interferes with human dendritic cell maturation and activation. J. Leukocyte Biol. 74:370.
26. Retini, C., A. Vecchiarelli, C. Monari, F. Bistoni, and T. R. Kozel. 1998. Encapsulation of Cryptococcus neoformans with glucuronoxylomannan inhibits the antigen-presenting capacity of monocytes. Infect. Immun. 66:664.
27. Syme, R. M., T. F. Bruno, T. R. Kozel, and C. H. Mody. 1999. The capsule of Cryptococcus neoformans reduces T-lymphocyte proliferation by reducing phagocytosis, which can be restored with anticapsular antibody. Infect. Immun. 67:4620.
28. Retini, C., A. Casadevall, D. Pietrella, C. Monari, B. Palazzetti, and A. Vecchiarelli. 1999. Specific activated T cells regulate IL-12 production by human monocytes stimulated with Cryptococcus neoformans. J. Immunol. 162:1618.
29. Monari, C., C. Retini, A. Casadevall, D. Netski, F. Bistoni, T. R. Kozel, and A. Vecchiarelli. 2003. Differences in outcome of the interaction between Cryptococcus neoformans glucuronoxylomannan and human monocytes and neutrophils. Eur. J. Immunol. 33:1041.
30. Vecchiarelli, A. 2000. Immunoregulation by capsular components of Cryptococcus neoformans. Med. Mycol. 38:407.
31. Monari, C., T. R. Kozel, F. Bistoni, and A. Vecchiarelli. 2002. Modulation of C5aR expression on human neutrophils by encapsulated and acapsular Cryptococcus neoformans. Infect. Immun. 70:3363.
32. Chiapello, L. S., M. P. Aoki, H. R. Rubinstein, and D. T. Masih. 2003. Apoptosis induction by glucuronoxylomannan of Cryptococcus neoformans. Med. Mycol. 41:347.
33. Mukherjee, S., S. C. Lee, and A. Casadevall. 1995. Antibodies to Cryptococcus neoformans glucuronoxylomannan enhance antifungal activity of murine macrophages. Infect. Immun. 63:573.
34. Mukherjee, S., S. Lee, J. Mukherjee, M. D. Scharff, and A. Casadevall. 1994. Monoclonal antibodies to Cryptococcus neoformans capsular polysaccharide modify the course of intravenous infection in mice. Infect. Immun. 62:1079.
35. Cherniak, R., E. Reiss, M. E. Slodki, R. D. Plattner, and S. O. Blumer. 1980. Structure and antigenic activity of the capsular polysaccharide of Cryptococcus neoformans serotype. A. Mol. Immunol. 17:1025.
36. Houpt, D. C., G. S. Pfrommer, B. J. Young, T. A. Larson, and T. R. Kozel. 1994. Occurrences, immunoglobulin classes, and biological activities of antibodies in normal human serum that are reactive with Cryptococcus neoformans glucuronoxylomannan. Infect. Immun. 62:2857.
37. Plesner, A., C. J. Greenbaum, and A. Lernmark. 2001. Low serum conditions for in vitro generation of human macrophages with macrophage colony stimulating factor. J. Immunol. Methods 249:53.
38. Weiner, S. M., C. Bianco, and V. Nussenzweig. 1973. Enhanced binding of neuraminidase-treated sheep erythrocytes to human T lymphocytes. Blood 42: 939.
39. Pauwels, R., J. Balzarini, M. Baba, R. Snoeck, D. Schols, P. Herdewijn, J. Desmyter, and E. De Clercq. 1988. Rapid and automated tetrazolium-based colorimetric assay for the detection of anti-HIV compounds. J. Virol. Methods 20:309.
40. Migliorati, G., I. Nicoletti, M. C. Pagliacci, L. D'Adamio, and C. Riccardi. 1993. Interleukin-4 protects double-negative and CD4 single-positive thymocytes from dexamethasone-induced apoptosis. Blood 81:1352.
41. Martin, S. J., C. P. Reutelingsperger, A. J. McGahon, J. A. Rader, R. C. van Schie, D. M. LaFace, and D. R. Green. 1995. Early redistribution of plasma membrane phosphatidylserine is a general feature of apoptosis regardless of the initiating stimulus: inhibition by overexpression of Bcl-2 and Abl. J. Exp. Med. 182:1545.
42. Bossi, G., and G. M. Griffiths. 1999. Degranulation plays an essential part in regulating cell surface expression of Fas ligand in T cells and natural killer cells. Nat. Med. 5:90.
43. Boyle, J. J. 2004. Human macrophages kill human mesangial cells by Fas-L-induced apoptosis when triggered by antibody via CD16. Clin. Exp. Immunol. 137:529.
44. Kiener, P. A., P. M. Davis, B. M. Rankin, S. J. Klebanolf, J. A. Ledbetter, G. C. Starling, and W. C. Liles. 1997. Human monocytic cells contain high levels of intracellular Fas ligand: rapid release following cellular activation. J. Immunol. 159:1594.
45. Nakajima, M., K. Kashiwagi, J. Ohta, S. Furukawa, K. Hayashi, T. Kawashima, and Y. Hayashi. 1994. Nerve growth factor and epidermal growth factor rescue PC12 cells from programmed cell death induced by etoposide: distinct modes of protection against cell death by growth factors and a protein-synthesis inhibitor. Neurosci. Lett. 176:161.
46. Haase, R., C. J. Kirschning, A. Sing, P. Schrottner, K. Fukase, S. Kusumoto, H. Wagner, J. Heesemann, and K. Ruckdeschel. 2003. A dominant role of Toll-like receptor 4 in the signaling of apoptosis in bacteria-faced macrophages. J. Immunol. 171:4294.
47. Zhang, Y., and J. B. Bliska. 2003. Role of Toll-like receptor signaling in the apoptotic response of macrophages to Yersinia infection. Infect. Immun. 71:1513.
48. Shoham, S., C. Huang, J. M. Chen, D. T. Golenbock, and S. M. Levitz. 2001. Toll-like receptor 4 mediates intracellular signaling without TNF-α release in response to Cryptococcus neoformans polysaccharide capsule. J. Immunol. 166:4620.
49. Monari, C., F. Bistoni, A. Casadevall, E. Pericolini, D. Pietrella, T. R. Kozel, and A. Vecchiarelli. 2004. Glucuronoxylomannan, a microbial compound, regulates expression of costimulatory molecules and production of cytokines in macrophages. J. Infect. Dis. 191:127.
50. Hsu, L. C., J. M. Park, K. Zhang, J. L. Luo, S. Maeda, R. J. Kaufman, L. Eckmann, D. G. Guiney, and M. Karin. 2004. The protein kinase PKR is required for macrophage apoptosis after activation of Toll-like receptor 4. Nature 428:341.
51. Martinez-Lorenzo, M. J., A. Anel, S. Gamen, I. Monleón, P. Lasierra, L. Larrad, A. Pineiro, M. A. Alava, and J. Naval. 1999. Activated human T cells release bioactive Fas ligand and APO2 ligand in microvesicles. J. Immunol. 163:1274.
52. Mariani, S. M., B. Matiba, C. Baumler, and P. H. Krammer. 1995. Regulation of cell surface APO-1/Fas (CD95) ligand expression by metalloproteases. Eur. J. Immunol. 25:2303.
53. Tanaka, M., T. Suda, K. Haze, N. Nakamura, K. Sato, F. Kimura, K. Motoyoshi, M. Mizuki, S. Tagawa, S. Ohga, et al. 1996. Fas ligand in human serum. Nat. Med. 2:317.
54. + T cells. Immunol. Rev. 146:223.
55. Suda, T., H. Hashimoto, M. Tanaka, T. Ochi, and S. Nagata. 1997. Membrane Fas ligand kills human peripheral blood T lymphocytes, and soluble Fas ligand blocks the killing. J. Exp. Med. 186:2045.
56. Oyaizu, N., N. Kayagaki, H. Yagita, S. Pahwa, and Y. Ikawa. 1997. Requirement of cell-cell contact in the induction of Jurkat T cell apoptosis: the membrane-anchored but not soluble form of FasL can trigger anti-CD3-induced apoptosis in Jurkat T cells. Biochem. Biophys. Res. Commun. 238:670.
57. Green, D. R., and T. A. Ferguson. 2001. The role of Fas ligand in immune privilege. Nat. Rev. Mol. Cell Biol. 2:917.
58. Li, X. K., T. Okuyama, A. Tamura, M. Fujino, N. Funeshima, Y. Kaneda, Y. Kita, S. Enosawa, H. Amemiya, and S. Suzuki. 1998. Prolonged survival of recipient rats with Fas-ligand-transfected liver allografts by using HVJ-liposome. Transplant. Proc. 30:943.
59. Bonfoco, E., P. M. Stuart, T. Brunner, T. Lin, T. S. Griffith, Y. Gao, H. Nakajima, P. A. Henkart, T. A. Ferguson, and D. R. Green. 1998. Inducible nonlymphoid expression of Fas ligand is responsible for superantigen-induced peripheral deletion of T cells. Immunity 9:711.
60. Grinsell, M., L. C. Weinhold, J. E. Cutler, Y. Han, and T. R. Kozel. 2001. In vivo clearance of glucuronoxylomannan, the major capsular polysaccharide of Cryptococcus neoformans: a critical role for tissue macrophages. J. Infect. Dis. 184:479.
61. Lendvai, N., A. Casadevall, Z. Liang, D. L. Goldman, J. Mukherjee, and L. Zuckier. 1998. Effect of immune mechanisms on the pharmacokinetics and organ distribution of cryptococcal polysaccharide. J. Infect. Dis. 177:1647.
62. Goldman, D. L., S. C. Lee, and A. Casadevall. 1995. Tissue localization of Cryptococcus neoformans glucuronoxylomannan in the presence and absence of specific antibody. Infect. Immun. 63:3448.
63. Lee, H. O., and T. A. Ferguson. 2003. Biology of FasL. Cytokine Growth Factor Rev. 14:325.
64. Hahne, M., D. Rimoldi, M. Schroter, P. Romero, M. Schreier, L. E. French, P. Schneider, T. Bornand, A. Fontana, D. Lienard, et al. 1996. Melanoma cell expression of Fas(Apo-1/CD95) ligand: implications for tumor immune escape. Science 274:1363.
65. Kaplan, H. J., M. A. Leibole, T. Tezel, and T. A. Ferguson. 1999. Fas ligand (CD95 ligand) controls angiogenesis beneath the retina. Nat. Med. 5:292.
66. Goldman, D., Y. Cho, M. Zhao, A. Casadevall, and S. C. Lee. 1996. Expression of inducible nitric oxide synthase in rat pulmonary Cryptococcus neoformans granulomas. Am. J. Pathol. 148:1275.
67. Gougeon, M. L., and L. Montagnier. 1999. Programmed cell death as a mechanism of CD4 and CD8 T cell deletion in AIDS: molecular control and effect of highly active anti-retroviral therapy. Ann. NY Acad. Sci. 887:199.
68. + T cells during experimental infection with Mycobacterium avium is controlled by Fas/FasL and Bcl-2-sensitive pathways, respectively. Immunol. Cell Biol. 81:480.
69. Zenewicz, L. A., J. A. Skinner, H. Goldfine, and H. Shen. 2004. Listeria monocytogenes virulence proteins induce surface expression of Fas ligand on T lymphocytes. Mol. Microbiol 51:1483.
70. Mirshafiey, A., M. Chitsaz, M. Attar, F. Mehrabian, and A. R. Razavi. 2000. Culture filtrate of Cryptococcus neoformans var. gattii (CneF) as a novel antiinflammatory compound in the treatment of experimental septic arthritis. Scand. J. Immunol. 52:278.
71. Mirshafiey, A., F. Mehrabian, A. Razavi, M. R. Shidfar, and S. Namaki. 2000. Novel therapeutic approach by culture filtrate of Cryptococcus neoformans var. gattii (CneF) in experimental immune complex glomerulonephritis. Gen. Pharmacol. 34:311.
72. Imai, T., S. Adachi, K. Nishijo, M. Ohgushi, M. Okada, T. Yasumi, K. Watanabe, R. Nishikomori, T. Nakayama, S. Yonehara, et al. 2003. FR901228 induces tumor regression associated with induction of Fas ligand and activation of Fas signaling in human osteosarcoma cells. Oncogene 22:9231.
73. Mishima, K., Y. Nariai, and Y. Yoshimura. 2003. Carboplatin induces FaS(APO-1/CD95)-dependent apoptosis of human tongue carcinoma cells: sensitization for apoptosis by up-regulation of FADD expression. Int. J. Cancer 105:593.
74. Campos, L., J. P. Rouauk, O. Sabido, P. Oriol, N. Roubi, C. Vasselon, E. Archimbaud, J. P. Magaud, and D. Guyotat. 1993. High expression of bcl-2 protein in acute myeloid leukemia cells is associated with poor response to chemotherapy. Blood 81:3091.
75. Miyashita, T., and J. C. Reed. 1993. Bcl-2 oncoprotein blocks chemotherapy-induced apoptosis in a human leukemia cell line. Blood 81:151.
76. Sinha, B. K., H. Yamazaki, H. M. Eliot, E. Schneider, M. M. Borner, and P. M. O'Connor. 1995. Relationships between proto-oncogene expression and apoptosis induced by anticancer drugs in human prostate tumor cells. Biochim. Biophys. Acta 1270:12.